Asia Gout Disease Treatment Market

Asia Gout Disease Treatment Market, By Drug Class (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, and Urate-lowering Agents), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Country (China, India, Japan, South Korea, Thailand, Indonesia, Singapore, Vietnam, and Rest of Asian Countries) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Gout is a chronic disease characterized by pain and inflammation in the joints. It is also known as gout arthritis, in which a high level of uric acid in the blood leads to the formation of needle-like crystals in the joints, resulting in inflammation and pain. This condition can be treated or prevented with the use of drugs such as nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and urate-lowering agents. Moreover, monoclonal antibodies is also used to treat gout in certain cases in which, nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and urate lowering agents are unresponsive to the patient.

Market Dynamics

Increasing prevalence of gout disease is expected to increase demand for anti-gout drugs, which is expected to drive growth of the Asia gout disease treatment market growth over the forecast period. For instance, according to the National Center for Biotechnology Information (NCBI) (Rheumatology journal), the prevalence of gout in 2021 increased in South Korea compared to 2007 (earlier reported prevalence). In 2020, the prevalence of gout disease in South Korea was 3.49 (3.48-3.51) per 1,000 persons, and in 2020, the prevalence of gout disease in South Korea was 7.58 (7.55-7.60) per 1,000 persons. Moreover, according to the data from the Australian Bureau of Statistics 2020–2021 (a National Health Survey), an estimated 187,000 people in Australia (0.8% of the population) were diagnosed with gout disease in 2021.

Moreover, increasing product approvals by regulatory authorities is expected to drive growth of the Asia gout disease treatment market. For instance, in July 2022, the United States Food and Drug Administration approved an expanded label of Horizon’s Krystexxa to improve the treatment outcomes for patients with uncontrolled gout. Also, in January 2021, Dr. Reddy’s Laboratories Ltd. ultinational pharmaceutical company based in India, launched Febuxostat Tablets, a therapeutic equivalent generic version of Uloric (Febuxostat) Tablets in the U.S. The tablets are available in 40 mg and 80 mg strengths in bottle count sizes of 30 tablets.

Key features of the study:

• This report provides an in-depth analysis of the Asia gout disease treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Asia gout disease treatment market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Teijin Pharma Limited, Hikma Pharmaceuticals Plc., Hikma Pharmaceuticals Plc., Zyla Life Sciences, Horizon Therapeutics plc, JW Pharmaceutical CORPORATION, Abbott Diagnostics (Abbott Laboratories), Labcorp ,Antibodies Inc., Networks LLC, Beckman Coulter, Inc., Euro Diagnostica AB, F. Hoffmann-La Roche Ltd., Qiagen NV, Siemens Healthcare GmbH, and Augurex Life Sciences Corp., Thermo Fisher Scientific Inc., Bio Rad Laboratories Inc., Exagen Inc., Genway Biotech, Inc., Microdrop LLC (imaware), Svar Life Science and LG Chem.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The Asia Gout disease treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Asia disease treatment market.

Detailed Segmentation:

• Asia Gout Disease Treatment Market, By Drug Class:
• Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
• Corticosteroids
• Colchicine
• Urate-lowering Agents
• Asia Gout Disease Treatment Market, By Route of Administration:
• Oral
• Injectable
• Asia Gout Disease Treatment Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Asia Gout Disease Treatment Market, By Region:
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Company Profiles
• AstraZeneca Plc
• Takeda Pharmaceutical Company Limited
• Teijin Pharma Limited
• Hikma Pharmaceuticals Plc.
• Zyla Life Sciences
• Horizon Therapeutics plc
• JW Pharmaceutical CORPORATION
• Abbott Diagnostics (Abbott Laboratories)
• Labcorp
• Antibodies Inc.
• Networks LLC
• Beckman Coulter, Inc
• Euro Diagnostica AB
• Hoffmann-La Roche Ltd.
• Qiagen NV
• Siemens Healthcare GmbH
• Augurex Life Sciences Corp.
• Thermo Fisher Scientific Inc.
• Bio Rad Laboratories Inc.
• Exagen Inc.
• Genway Biotech, Inc.
• Microdrop LLC (imaware)
• Svar Life Science
• LG Chem.